在多发性骨髓瘤中,MDM2和NF-κB蛋白表达的关联和重要性
Marija Stanić Damić1,2, Aron Grubešić1,2, Zinaida Perić1,2
1Department of Internal Medicine, Division of Hematology, Clinical Hospital Center Rijeka, Krešimirova 42, 51000 Rijeka, Croatia.
Medicina (Kaunas, Lithuania)
|November 27, 2025
概括
这项研究发现,博特佐米布治疗降低了多发性骨髓瘤患者的MDM2和NF-κB蛋白表达. 较低的NF-κB水平预测治疗后功能更好.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 多发性骨髓瘤是一种血细胞的癌症.
- 博尔特佐米布是一种蛋白酶体抑制剂,用于治疗多发性骨髓瘤.
- MDM2和NF-κB蛋白质在癌细胞生存和耐药性方面发挥作用.
研究的目的:
- 在多发性骨髓瘤患者中研究MDM2和NF-κB蛋白的表达,这些患者接受了博特佐米布治疗.
- 探索MDM2和NF-κB之间的相互作用及其与临床结果的相关性.
主要方法:
- 从多发性骨髓瘤患者的骨髓活检中进行双重免疫组织化学染色.
- 基于博尔特佐米布的治疗前后蛋白质表达的分析.
- 统计分析以将蛋白质水平与临床和预后因素相关联.
主要成果:
- 在MDM2和NF-κB表达之间观察到正相关性.
- 博尔特佐米布治疗导致MDM2和NF-κB表达的显著下降.
- 减少NF-κB表达被确定为改善功能的一个独立预后因素.
结论:
- 这项研究是第一个在多发性骨髓瘤患者骨髓中体内MDM2蛋白表达的研究.
- 博尔特佐米布治疗可能会影响多发性骨髓瘤微环境中的MDM2表达.
- 抑制NF-κB可能是改善多发性骨髓瘤结局的治疗标.
关键词:
MDM2DM2 在线播放在 NF-κBB 中.生物标志物生物标志物博尔特佐米布 (Bortezomib) 是一种药物.多发性骨髓瘤是多发性骨髓瘤的一种.蛋白质表达 蛋白质表达患有功能障碍的人.更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
7.2K
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.6K
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Master Transcription Regulators
7.7K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.7K
NF-κB-dependent Signaling Pathway
9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.7K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
